Trial
NCT02707666
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Chicago
Collaborators
—
Condition
Pleural Mesothelioma
Intervention
Pembrolizumab
Why stopped
unable to complete enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-31